ON LINKEDIN
Meet us in Baltimore October 24-28 for the American Society for Reproductive Medicine (#ASRM) Congress. We'll be presenting research on ABS-201, a novel AI-designed monoclonal antibody in Phase 1/2a clinical trial. Last month Absci announced preliminary details for STORYLINE™, a Phase 2 Trial investigating ABS-201 for endometriosis. Poster Title: "P-37 Prolactin Receptor Blockade with Anti-Prolactin Receptor Antibody (Anti- PRLR AB) Relieves Pain and Inflammation in a Homologous Transplant Mouse Model of Endometriosis" 🗓️When: Monday, Oct 26 | 12 PM ET 📍Where: Baltimore Convention Center
As part of our commitment to advancing women's health, Absci recently announced key design details for our planned Phase 2 STORYLINE™ clinical trial evaluating ABS-201, an AI-designed therapeutic with the potential to offer a novel, non-sex-hormonal approach to treating endometriosis. An estimated 190 million women and girls worldwide live with endometriosis, a painful condition in which endometriotic lesions grow outside the uterus. Many people with this condition face diagnostic delays, access gaps, and limited treatment options. Current FDA-approved medical treatments are sex-hormone therapies that affect estrogen, and surgical lesion removal has recurrence rates nearing 50% within five years. ABS-201 is an antibody targeting the prolactin receptor that has the potential to offer durable relief for endometriosis-associated pain (EAP). Learn more about ABS-201 and our Phase 2 STORYLINE™ trial: https://lnkd.in/g--gAtve
We'll be at the 35th European Academy of Dermatology and Venereology (#EADV2026) Congress in Vienna! Join us September 30 – October 3 at the Austria Center Vienna, where we'll share more about our internal pipeline program for pattern hair loss. ABS-201 is a novel, AI-designed monoclonal antibody currently being evaluated in the Phase 1/2a HEADLINE Clinical Trial. Poster: Prolactin Receptor Antagonism by ABS-201 Drives Hair Follicle Growth and Stem/Progenitor Cell Expansion in Human Male Scalp Skin